BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-2.68%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$17.3B
AUM Growth
+$17.3B
(-6%)
Cap. Flow
-$421M
Cap. Flow
% of AUM
-2.43%
Top 10 Holdings %
Top 10 Hldgs %
87.61%
Holding
112
New
6
Increased
20
Reduced
13
Closed
5
Top Buys
| 1 |
Roivant Sciences
ROIV
|
$46.9M |
| 2 |
AbCellera Biologics
ABCL
|
$38.8M |
| 3 |
Kymera Therapeutics
KYMR
|
$34.4M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$28.7M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$22.2M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$454M |
| 2 |
Krystal Biotech
KRYS
|
$15.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$15M |
| 4 |
FibroGen
FGEN
|
$6.48M |
| 5 |
Verastem
VSTM
|
$5.88M |
Sector Composition
| 1 | Healthcare | 99.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Denali Therapeutics
DNLI
$2.24B
| $42.9M | 0.25% |
1,455,322
+366,584
| +34% | +$10.8M |
|
27
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $39.6M | 0.23% |
2,809,577
+10,000
| +0.4% | +$141K |
|
28
Cerus
CERS
$251M
| $39.5M | 0.23% |
16,067,558
| – | – |
|
29
Nurix Therapeutics
NRIX
$723M
| $38.8M | 0.22% |
3,882,125
| – | – |
|
30
Ultragenyx Pharmaceutical
RARE
$3.04B
| $36.1M | 0.21% |
783,059
+312,085
| +66% | +$14.4M |
|
|
JBIO
31
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $33.7M | 0.19% |
1,963,479
| – | – |
|
|
IGMS
32
DELISTED
IGM Biosciences
IGMS
| $29.1M | 0.17% |
3,157,210
+554
| +0% | +$5.11K |
|
33
Xenon Pharmaceuticals
XENE
$2.99B
| $28.9M | 0.17% |
751,639
| – | – |
|
|
IMGN
34
DELISTED
Immunogen Inc
IMGN
| $28.7M | 0.17% |
+1,520,097
| New | +$28.7M |
|
|
DBVT
35
DBV Technologies
DBVT
$249M
| $27.8M | 0.16% |
14,614,264
| – | – |
|
|
VERV
36
DELISTED
Verve Therapeutics
VERV
| $26.6M | 0.15% |
1,416,530
| – | – |
|
|
TSVT
37
DELISTED
2seventy bio
TSVT
| $25.3M | 0.15% |
2,497,526
| – | – |
|
38
IDEAYA Biosciences
IDYA
$2.26B
| $25M | 0.14% |
1,062,123
+229,354
| +28% | +$5.39M |
|
39
Stoke Therapeutics
STOK
$1.08B
| $22.6M | 0.13% |
2,130,238
+14,822
| +0.7% | +$158K |
|
|
BCYC
40
Bicycle Therapeutics
BCYC
$492M
| $21.5M | 0.12% |
843,814
| – | – |
|
41
Monte Rosa Therapeutics
GLUE
$309M
| $20.7M | 0.12% |
3,023,951
+2,648,856
| +706% | +$18.1M |
|
42
Cabaletta Bio
CABA
$144M
| $20.6M | 0.12% |
1,594,000
+250,000
| +19% | +$3.23M |
|
|
43
Krystal Biotech
KRYS
$4.35B
| $20M | 0.12% |
169,934
-132,782
| -44% | -$15.6M |
|
44
Summit Therapeutics
SMMT
$17.5B
| $15.8M | 0.09% |
6,304,705
| – | – |
|
45
AnaptysBio
ANAB
$630M
| $15.8M | 0.09% |
775,924
| – | – |
|
46
Prime Medicine
PRME
$595M
| $15.1M | 0.09% |
1,028,466
| – | – |
|
47
Pacific Biosciences
PACB
$378M
| $15M | 0.09% |
1,127,782
| – | – |
|
48
Relay Therapeutics
RLAY
$709M
| $14.6M | 0.08% |
1,160,117
+876,117
| +308% | +$11M |
|
49
ARS Pharmaceuticals
SPRY
$1.08B
| $13.4M | 0.08% |
2,006,451
| – | – |
|
50
Day One Biopharmaceuticals
DAWN
$766M
| $11.9M | 0.07% |
+1,000,000
| New | +$11.9M |
|